trending Market Intelligence /marketintelligence/en/news-insights/trending/04iDOaR5STaPdmgMRf5yTw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

FDA Watch: Approval for Grifols; designation for Novartis

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


FDA Watch: Approval for Grifols; designation for Novartis

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Jan. 11.

SNL Image
FDA headquarters in Silver Spring, Md.
Source: Associated Press

Approvals

* Grifols SA's Erytra Eflexis, to analyze the compatibility of blood between transfusion recipients and donors.

Breakthrough therapy

* Novartis AG's crizanlizumab, to prevent vaso-occlusive crises in patients with sickle cell disease. Novartis said it plans to file for FDA approval of the drug, also known as SEG101, in the first half of 2019.